Literature DB >> 18081539

Current use and development of vaccines for Japanese encephalitis.

David W C Beasley1, Penny Lewthwaite, Tom Solomon.   

Abstract

BACKGROUND: Japanese encephalitis (JE) is a significant cause of human morbidity and mortality throughout Asia. Vaccines for JE have been available for many years and their use has been effective in reducing the incidence of JE disease in several countries but, as disease incidence has decreased, concerns regarding adverse events following immunisation have increased.
OBJECTIVE: To review existing JE vaccines and new candidates in advanced preclinical or clinical evaluation.
METHODS: The review primarily covers published and some unpublished literature from the past decade describing current use of approved JE vaccines in various parts of the world, and advanced development and clinical testing of alternative vaccine candidates. RESULTS/
CONCLUSION: There is a clear need for additional licensing of existing or new JE vaccines. Several promising candidates are currently in use or completing clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18081539     DOI: 10.1517/14712598.8.1.95

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  36 in total

Review 1.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

Review 2.  Degrees of maturity: the complex structure and biology of flaviviruses.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2012-03-23       Impact factor: 7.090

3.  Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.

Authors:  Emmanuel Feroldi; Maria Rosario Capeding; Mark Boaz; Sophia Gailhardou; Claude Meric; Alain Bouckenooghe
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

4.  Japanese encephalitis in travelers from non-endemic countries, 1973-2008.

Authors:  Susan L Hills; Anne C Griggs; Marc Fischer
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

5.  Genetic and phenotypic properties of vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice.

Authors:  Gregory D Gromowski; Cai-Yen Firestone; José Bustos-Arriaga; Stephen S Whitehead
Journal:  Am J Trop Med Hyg       Date:  2014-10-13       Impact factor: 2.345

6.  PCP consensus sequences of flaviviruses: correlating variance with vector competence and disease phenotype.

Authors:  Petr Danecek; Wenzhe Lu; Catherine H Schein
Journal:  J Mol Biol       Date:  2009-12-04       Impact factor: 5.469

7.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.

Authors:  Mario Lobigs; Megan Pavy; Roy A Hall; Päivi Lobigs; Peter Cooper; Tomoyoshi Komiya; Hiroko Toriniwa; Nikolai Petrovsky
Journal:  J Gen Virol       Date:  2010-02-03       Impact factor: 3.891

Review 8.  Chikungunya: a potentially emerging epidemic?

Authors:  Michelle M Thiboutot; Senthil Kannan; Omkar U Kawalekar; Devon J Shedlock; Amir S Khan; Gopalsamy Sarangan; Padma Srikanth; David B Weiner; Karuppiah Muthumani
Journal:  PLoS Negl Trop Dis       Date:  2010-04-27

9.  Past, present, and future of Japanese encephalitis.

Authors:  Susan L Hills; Deborah C Phillips
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

10.  Chikungunya virus and central nervous system infections in children, India.

Authors:  Penny Lewthwaite; Ravi Vasanthapuram; Jane C Osborne; Ashia Begum; Jenna L M Plank; M Veera Shankar; Roger Hewson; Anita Desai; Nick J Beeching; Ravi Ravikumar; Tom Solomon
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.